糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

CDS 2013：贾伟平谈中国慢性病防控策略核心内容

2013-11-23 MedSci MedSci原创

贾伟平慢性病CDS
关注

      11月22日，在中华医学会糖尿病学分会第十七次全国学术会议(CDS2013)“糖尿病转化医学”专题研讨会上，上海市第六人民医院贾伟平教授作了题为“三级医院的防治成效向社区的转化”的报告，她指出社区糖尿病防治存在血糖控制差、忽视并发症筛查、缺乏糖尿病综合管理团队等问题。  

      11月22日，在中华医学会糖尿病学分会第十七次全国学术会议(CDS2013)“糖尿病转化医学”专题研讨会上，上海市第六人民医院贾伟平教授作了题为“三级医院的防治成效向社区的转化”的报告，她指出社区糖尿病防治存在血糖控制差、忽视并发症筛查、缺乏糖尿病综合管理团队等问题。


  

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941950, encodeId=6d1f1941950fd, content=<a href='/topic/show?id=dbf89e4006a' target=_blank style='color:#2F92EE;'>#防控策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97400, encryptionId=dbf89e4006a, topicName=防控策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Mar 12 05:38:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070015, encodeId=5c3620e00154a, content=<a href='/topic/show?id=bece92532e4' target=_blank style='color:#2F92EE;'>#贾伟平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92532, encryptionId=bece92532e4, topicName=贾伟平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Tue Mar 04 06:38:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263981, encodeId=a9df126398162, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Mon Nov 25 13:38:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377565, encodeId=b5ae13e7565aa, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 13:38:00 CST 2013, time=2013-11-25, status=1, ipAttribution=)]
    2014-03-12 millore

    #防控策略#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1941950, encodeId=6d1f1941950fd, content=<a href='/topic/show?id=dbf89e4006a' target=_blank style='color:#2F92EE;'>#防控策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97400, encryptionId=dbf89e4006a, topicName=防控策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Mar 12 05:38:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070015, encodeId=5c3620e00154a, content=<a href='/topic/show?id=bece92532e4' target=_blank style='color:#2F92EE;'>#贾伟平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92532, encryptionId=bece92532e4, topicName=贾伟平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Tue Mar 04 06:38:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263981, encodeId=a9df126398162, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Mon Nov 25 13:38:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377565, encodeId=b5ae13e7565aa, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 13:38:00 CST 2013, time=2013-11-25, status=1, ipAttribution=)]
    2014-03-04 3631173

    #贾伟平#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1941950, encodeId=6d1f1941950fd, content=<a href='/topic/show?id=dbf89e4006a' target=_blank style='color:#2F92EE;'>#防控策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97400, encryptionId=dbf89e4006a, topicName=防控策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Mar 12 05:38:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070015, encodeId=5c3620e00154a, content=<a href='/topic/show?id=bece92532e4' target=_blank style='color:#2F92EE;'>#贾伟平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92532, encryptionId=bece92532e4, topicName=贾伟平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Tue Mar 04 06:38:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263981, encodeId=a9df126398162, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Mon Nov 25 13:38:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377565, encodeId=b5ae13e7565aa, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 13:38:00 CST 2013, time=2013-11-25, status=1, ipAttribution=)]
    2013-11-25 qjddjq

    #慢性病#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1941950, encodeId=6d1f1941950fd, content=<a href='/topic/show?id=dbf89e4006a' target=_blank style='color:#2F92EE;'>#防控策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97400, encryptionId=dbf89e4006a, topicName=防控策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed Mar 12 05:38:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070015, encodeId=5c3620e00154a, content=<a href='/topic/show?id=bece92532e4' target=_blank style='color:#2F92EE;'>#贾伟平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92532, encryptionId=bece92532e4, topicName=贾伟平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Tue Mar 04 06:38:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263981, encodeId=a9df126398162, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Mon Nov 25 13:38:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377565, encodeId=b5ae13e7565aa, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 13:38:00 CST 2013, time=2013-11-25, status=1, ipAttribution=)]
    2013-11-25 yangpeizhi

    #CDS#

    0